158 related articles for article (PubMed ID: 33153234)
1. The Pyrazolo[3,4-
Neuber C; Tröster A; Löser R; Belter B; Schwalbe H; Pietzsch J
Molecules; 2020 Nov; 25(21):. PubMed ID: 33153234
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments.
Neuber C; Belter B; Meister S; Hofheinz F; Bergmann R; Pietzsch HJ; Pietzsch J
Molecules; 2018 Feb; 23(2):. PubMed ID: 29462967
[TBL] [Abstract][Full Text] [Related]
3. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.
Martiny-Baron G; Holzer P; Billy E; Schnell C; Brueggen J; Ferretti M; Schmiedeberg N; Wood JM; Furet P; Imbach P
Angiogenesis; 2010 Sep; 13(3):259-67. PubMed ID: 20803239
[TBL] [Abstract][Full Text] [Related]
4. NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
Tröster A; Heinzlmeir S; Berger BT; Gande SL; Saxena K; Sreeramulu S; Linhard V; Nasiri AH; Bolte M; Müller S; Kuster B; Médard G; Kudlinzki D; Schwalbe H
ChemMedChem; 2018 Aug; 13(16):1629-1633. PubMed ID: 29928781
[TBL] [Abstract][Full Text] [Related]
5. EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Becerikli M; Merwart B; Lam MC; Suppelna P; Rittig A; Mirmohammedsadegh A; Stricker I; Theiss C; Singer BB; Jacobsen F; Steinstraesser L
Int J Cancer; 2015 Apr; 136(8):1781-91. PubMed ID: 25274141
[TBL] [Abstract][Full Text] [Related]
6. Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.
Donnini S; Monti M; Castagnini C; Solito R; Botta M; Schenone S; Giachetti A; Ziche M
Int J Cancer; 2007 Mar; 120(5):995-1004. PubMed ID: 17131343
[TBL] [Abstract][Full Text] [Related]
7. EphB4/ TNFR2/ERK/MAPK signaling pathway comprises a signaling axis to mediate the positive effect of TNF-α on osteogenic differentiation.
Zhang Y; Yang C; Ge S; Wang L; Zhang J; Yang P
BMC Mol Cell Biol; 2020 Apr; 21(1):29. PubMed ID: 32299362
[TBL] [Abstract][Full Text] [Related]
8. EphB4 forward signalling mediates angiogenesis caused by CCM3/PDCD10-ablation.
You C; Zhao K; Dammann P; Keyvani K; Kreitschmann-Andermahr I; Sure U; Zhu Y
J Cell Mol Med; 2017 Sep; 21(9):1848-1858. PubMed ID: 28371279
[TBL] [Abstract][Full Text] [Related]
9. The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study.
Kathawala RJ; Wei L; Anreddy N; Chen K; Patel A; Alqahtani S; Zhang YK; Wang YJ; Sodani K; Kaddoumi A; Ashby CR; Chen ZS
Oncotarget; 2015 Jan; 6(1):510-21. PubMed ID: 25402202
[TBL] [Abstract][Full Text] [Related]
10. Resistance to bevacizumab in ovarian cancer SKOV3 xenograft due to EphB4 overexpression.
Li L; Nan F; Guo Q; Guan D; Zhou C
J Cancer Res Ther; 2019; 15(6):1282-1287. PubMed ID: 31898661
[TBL] [Abstract][Full Text] [Related]
11. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways.
Shi X; Zhu M; Gong Z; Yang T; Yu R; Wang J; Zhang Y
Food Chem Toxicol; 2020 Feb; 136():110960. PubMed ID: 31726078
[TBL] [Abstract][Full Text] [Related]
12. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
Aslam MI; Abraham J; Mansoor A; Druker BJ; Tyner JW; Keller C
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6383-8. PubMed ID: 24733895
[TBL] [Abstract][Full Text] [Related]
13. EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2.
Héroult M; Schaffner F; Pfaff D; Prahst C; Kirmse R; Kutschera S; Riedel M; Ludwig T; Vajkoczy P; Graeser R; Augustin HG
Mol Cancer Res; 2010 Oct; 8(10):1297-309. PubMed ID: 21047731
[TBL] [Abstract][Full Text] [Related]
14. Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model.
Broggini T; Piffko A; Hoffmann CJ; Ghori A; Harms C; Adams RH; Vajkoczy P; Czabanka M
Oncogene; 2020 Nov; 39(47):7063-7075. PubMed ID: 32989254
[TBL] [Abstract][Full Text] [Related]
15. EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis.
Huang X; Yamada Y; Kidoya H; Naito H; Nagahama Y; Kong L; Katoh SY; Li WL; Ueno M; Takakura N
Cancer Res; 2007 Oct; 67(20):9800-8. PubMed ID: 17942910
[TBL] [Abstract][Full Text] [Related]
16. Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.
Xiong C; Wen Y; Zhao J; Yin D; Xu L; Chelariu-Raicu A; Yao C; Leng X; Liu J; Chaudhari RR; Zhang S; Sood AK; Li C
Sci Rep; 2020 Jan; 10(1):520. PubMed ID: 31949258
[TBL] [Abstract][Full Text] [Related]
17. Targeting receptor tyrosine kinase EphB4 in cancer therapy.
Chen Y; Zhang H; Zhang Y
Semin Cancer Biol; 2019 Jun; 56():37-46. PubMed ID: 28993206
[TBL] [Abstract][Full Text] [Related]
18. EphB4 signaling is capable of mediating ephrinB2-induced inhibition of cell migration.
Sturz A; Bader B; Thierauch KH; Glienke J
Biochem Biophys Res Commun; 2004 Jan; 313(1):80-8. PubMed ID: 14672701
[TBL] [Abstract][Full Text] [Related]
19. Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma.
DiPrima M; Wang D; Tröster A; Maric D; Terrades-Garcia N; Ha T; Kwak H; Sanchez-Martin D; Kudlinzki D; Schwalbe H; Tosato G
Mol Oncol; 2019 Nov; 13(11):2441-2459. PubMed ID: 31545551
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4.
Suzuki M; Abe A; Imagama S; Nomura Y; Tanizaki R; Minami Y; Hayakawa F; Ito Y; Katsumi A; Yamamoto K; Emi N; Kiyoi H; Naoe T
Eur J Haematol; 2010 Mar; 84(3):229-38. PubMed ID: 20002159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
